Gary B. Nickol

Array ( [id] => 20568559 [patent_doc_number] => 20260062480 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-03-05 [patent_title] => HUMAN BLOOD-BRAIN BARRIER TARGETING ANTIBODIES [patent_app_type] => utility [patent_app_number] => 19/384776 [patent_app_country] => US [patent_app_date] => 2025-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17850 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 815 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19384776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20510134 [patent_doc_number] => 20260034233 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-02-05 [patent_title] => ANTI-GALECTIN 3 ANTIBODIES AND THEIR USE IN EPILEPSY AND RELATED DISEASES [patent_app_type] => utility [patent_app_number] => 19/347462 [patent_app_country] => US [patent_app_date] => 2025-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59573 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 172 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19347462 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20803731 [patent_doc_number] => 12668627 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-06-30 [patent_title] => Cytokine-based therapies and methods [patent_app_type] => utility [patent_app_number] => 19/205170 [patent_app_country] => US [patent_app_date] => 2025-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 73 [patent_no_of_words] => 28923 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 238 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19205170 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19299997 [patent_doc_number] => 20240228566 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => COMPOSITIONS AND METHODS FOR VASCULAR PROTECTION AFTER MYOCARDIAL ISCHEMIA [patent_app_type] => utility [patent_app_number] => 18/431661 [patent_app_country] => US [patent_app_date] => 2024-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15511 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18431661 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19418528 [patent_doc_number] => 20240294651 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/425119 [patent_app_country] => US [patent_app_date] => 2024-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71864 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18425119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19097838 [patent_doc_number] => 20240117066 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => ANTI-UPAR ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/535012 [patent_app_country] => US [patent_app_date] => 2023-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30179 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 609 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18535012 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19543172 [patent_doc_number] => 20240360208 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => BISPECIFIC ANTI-CCL2 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/533714 [patent_app_country] => US [patent_app_date] => 2023-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58762 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18533714 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19233773 [patent_doc_number] => 20240190965 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => TARGETING ANTI-HUMAN PD 1H/VISTA TO TREAT HEMATOLOGIC DISORDERS [patent_app_type] => utility [patent_app_number] => 18/531168 [patent_app_country] => US [patent_app_date] => 2023-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16110 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18531168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19345287 [patent_doc_number] => 20240254250 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => BCMA TARGETING TRISPECIFIC PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/524822 [patent_app_country] => US [patent_app_date] => 2023-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18524822 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19263619 [patent_doc_number] => 20240207316 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => CHIMERIC RECEPTOR FOR IMPROVING KILLING ACTIVITY OF IMMUNE CELLS AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/516502 [patent_app_country] => US [patent_app_date] => 2023-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6162 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18516502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19431073 [patent_doc_number] => 20240299571 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => ANTI-FOLR1 IMMUNOCONJUGATES AND ANTI-PD-1 ANTIBODY COMBINATIONS [patent_app_type] => utility [patent_app_number] => 18/489292 [patent_app_country] => US [patent_app_date] => 2023-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21051 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -61 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18489292 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067223 [patent_doc_number] => 20240101649 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => ANTI-CfaE ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/481440 [patent_app_country] => US [patent_app_date] => 2023-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23629 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18481440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18901423 [patent_doc_number] => 20240016908 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 18/451216 [patent_app_country] => US [patent_app_date] => 2023-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37457 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18451216 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19032489 [patent_doc_number] => 20240082304 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => ANTIGEN-SPECIFIC T CELL RECEPTORS AND CHIMERIC ANTIGEN RECEPTORS, AND METHODS OF USE IN IMMUNE SIGNALING MODULATION FOR CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 18/212127 [patent_app_country] => US [patent_app_date] => 2023-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18212127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19142207 [patent_doc_number] => 20240141033 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-02 [patent_title] => COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34 [patent_app_type] => utility [patent_app_number] => 18/297099 [patent_app_country] => US [patent_app_date] => 2023-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13434 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18297099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18672934 [patent_doc_number] => 20230310385 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI-ESTROGEN [patent_app_type] => utility [patent_app_number] => 18/121075 [patent_app_country] => US [patent_app_date] => 2023-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18850 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18121075 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18861975 [patent_doc_number] => 20230416411 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => ANTIBODIES BINDING TO CD3 AND FOLR1 [patent_app_type] => utility [patent_app_number] => 18/066526 [patent_app_country] => US [patent_app_date] => 2022-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56833 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18066526 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18468915 [patent_doc_number] => 20230203199 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => ANTIGEN BINDING POLYPEPTIDES, ANTIGEN BINDING POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/936041 [patent_app_country] => US [patent_app_date] => 2022-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 189408 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17936041 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18208498 [patent_doc_number] => 20230054756 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => COMPOSITION FOR DIFFERENTIAL DIAGNOSIS OF ACANTHAMOEBA KERATITIS COMPRISING CHORISMATE MUTASE PROTEIN ANTIBODIES, AND ACANTHAMOEBA KERATITIS DIAGNOSIS KIT USING SAME [patent_app_type] => utility [patent_app_number] => 17/817459 [patent_app_country] => US [patent_app_date] => 2022-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2509 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17817459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19510636 [patent_doc_number] => 20240342322 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => Netrin-1 detection, companion test and therapy based on radiations [patent_app_type] => utility [patent_app_number] => 18/291972 [patent_app_country] => US [patent_app_date] => 2022-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11152 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18291972 [rel_patent_id] =>[rel_patent_doc_number] =>)